18F-FDG PET/CT in response evaluation of gastrointestinal stromal tumours treated with imatinib

Banzo, Ignacio; Quirce, R.; Martínez-Rodríguez, I.; Jiménez-Bonilla, J.; Sainz-Esteban, Aurora; Barragán, Jorge; Portilla-Quattrociocchi, H.; Carril, J.M.

doi:10.1016/s1578-200x(08)70034-2

Search citation statements

Order By: Relevance

Paper Sections

Select...

Discussion1

Targeted Therapy Of Gists With Imatinib Mesylate1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2010

2014

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(2 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been reported that many GISTs may not change significantly in size during early response to imatinib mesylate administration (8). PET has been shown to be highly sensitive in detecting early response to imatinib mesylate therapy (8,9). It has been reported that density reduction on CT reflects necrotic changes in the tumor and is a predictor of early response to imatinib mesylate therapy.…”

Section: Discussionmentioning

confidence: 99%

Relationship between FDG uptake and the pathological risk category in gastrointestinal stromal tumors

et al. 2010

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Relationship between FDG uptake and the pathological risk category in gastrointestinal stromal tumors

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Imaging of GIST patients is done with structural and functional methods such as contrast-enhanced helical computed tomography (CT) and positron emission tomography (PET) with 18F-fluorodeoxyglucose (FDG) [82]. Although CT shows greater anatomic detail, FDG PET can reveal small metastases and establish baseline metabolic activity, which can later aid in assessing the response to therapy and is a strong predictor of clinical outcome [83,84].…”

Section: Targeted Therapy Of Gists With Imatinib Mesylatementioning

confidence: 99%

Gastrointestinal stromal tumour: From the clinic to the molecules

Hapková¹,

Bernex²,

Pds³

et al. 2014

J Cancer Res Ther

View full text Add to dashboard Cite

GastroIntestional stromal tumours (GISTs), the most frequent sarcoma in the gastro-intestinal (GI) tract, are highly resistant to conventional chemotherapy and radiotherapy. These tumours have activating mutations in two closely related genes, KIT (75-80%) or/and PDGFRA (5-10%). Targeting these mutated activated proteins with imatinib mesylate has proven efficient in the treatment of GISTs. The median survival after diagnosis of GIST increased from 1.5 to 4.8 years with imatinib treatment. However, resistance to imatinib eventually develops and new-targeted therapies are needed. This paper reviews the medical, clinical and pathological aspects of GISTs based on latest research in human cell lines and animal models.Citation: Hapkova I, Bernex F, Barbara PDS, Vesely J (2014) Gastrointestinal stromal tumour: From the clinic to the molecules.

show abstract

18F-FDG PET/CT in response evaluation of gastrointestinal stromal tumours treated with imatinib

Cited by 2 publications

References 24 publications

Relationship between FDG uptake and the pathological risk category in gastrointestinal stromal tumors

Relationship between FDG uptake and the pathological risk category in gastrointestinal stromal tumors

Gastrointestinal stromal tumour: From the clinic to the molecules

Contact Info

Product

Resources

About